Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL)

Barbara Eichhorst; Michael Hallek

doi:10.1016/j.beha.2007.02.002

Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL)

Best Pract Res Clin Haematol. 2007 Sep;20(3):469-77. doi: 10.1016/j.beha.2007.02.002.

Authors

Barbara Eichhorst¹, Michael Hallek

Affiliation

¹ Klinik I für Innere Medizin, Universität zu Köln, Kerpenerstr. 62, D-50924 Köln, Germany.

PMID: 17707834
DOI: 10.1016/j.beha.2007.02.002

Abstract

During the past 10 years, significant progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options in chronic lymphocytic leukemia (CLL). These developments have led to revision of the National Cancer Institute-sponsored Working Group (NCI-WG) guidelines on CLL established in 1988 and 1996. The update of these guidelines will clarify the role of new prognostic markers in CLL, improve the definitions of response and refractory disease, and add information on the prevention and management of infectious and autoimmune complications.

MeSH terms

Clinical Trials as Topic / standards
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
National Institutes of Health (U.S.)
Neoplasm, Residual
Practice Guidelines as Topic
United States